Brian Park, PharmD

Drug Information Specialist https://www.cancertherapyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Lymphoma

FDA Grants Accelerated Approval to Brukinsa for Mantle Cell Lymphoma

Brian Park, PharmD

November 15, 2019

Continued approval may be contingent upon verification of clinical benefit in a confirmatory trial.

General Oncology

Ziextenzo, a Biosimilar to Neulasta, Receives FDA Approval

Brian Park, PharmD

November 6, 2019

The FDA has approved Ziextenzo (pegfilgrastim-bmez; Sandoz), a biosimilar to Neulasta.

Pancreatic Cancer

Development of Pancreatic Cancer Tx to Be Discontinued Following Disappointing Trial Results

Brian Park, PharmD

November 5, 2019

Halozyme Therapeutics announced that the phase 3 HALO-301 study of PEGPH20 as a first-line therapy for treatment of patients with metastatic pancreatic cancer has failed to meet the primary end point of overall survival.

Gynecologic Cancer

Zejula Approved for Late-line Treatment of Recurrent Ovarian Cancer

Brian Park, PharmD

October 25, 2019

Zejula, a poly(ADP-ribose) polymerase (PARP) inhibitor, is also approved for maintenance treatment in adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

General Oncology

BCG Vaccination and Cancer Risk: What’s the Link?

Brian Park, PharmD

September 26, 2019

Study authors suggest a more complete analysis of the lung’s response to BCG vaccination needs to be conducted in human trials.

Prostate Cancer

Erleada Approved for Metastatic Castration-Sensitive Prostate Cancer

Brian Park, PharmD

September 20, 2019

Erleada plus ADT achieved statistical significance in meeting both primary end points of OS and rPFS in the phase 3 TITAN study.

Breast Cancer

FDA Warns of Possible Interstitial Lung Disease, Pneumonitis With Certain Breast Cancer Drugs

Brian Park, PharmD

September 16, 2019

Healthcare professionals are being advised to monitor patients regularly for pulmonary symptoms indicative of ILD and/or pneumonitis, including hypoxia, cough, dyspnea, and interstitial infiltrates on radiologic exams.

Lung Cancer

Rova-T R&D Program Discontinued Following Poor Results in Lung Cancer Trial

Brian Park, PharmD

September 4, 2019

AbbVie has announced that the research and development program for its investigational drug, Rova-T will be terminated based on a lack of survival benefit in the phase 3 MERU trial.

General Oncology

Cancer Risk From Recalled ARBs “Likely Much Lower” Than Initially Estimated, Says FDA

Brian Park, PharmD

September 4, 2019

The FDA clarified that the risk of cancer associated with exposure to nitrosamine impurities was likely lower than what was initially assessed.

Multiple Myeloma

New Treatment Option Approved for Patients With Myelofibrosis

Brian Park, PharmD

August 20, 2019

The FDA has approved Inrebic (fedratinib; Celgene) capsules to treat adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.

Next post in Multiple Myeloma